{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:25:29Z","timestamp":1789118729896,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02192-2","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:33:33Z","timestamp":1784900013000},"page":"2179-2186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5847-0174","authenticated-orcid":false,"given":"Edel","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-6801","authenticated-orcid":false,"given":"Kate E.","family":"Coakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-7950","authenticated-orcid":false,"given":"Siobh\u00e1n","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"McDonagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-9477","authenticated-orcid":false,"given":"Laura J.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-7336","authenticated-orcid":false,"given":"S\u00e9amus","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Biologics Impact on Patient Care and Treatment (Bio ImPAcT) Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Fitzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobh\u00e1n","family":"Lucey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobh\u00e1n","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ilis J.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad M.","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"12","key":"2192_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190147","volume":"12","author":"E Moorkens","year":"2017","unstructured":"Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12(12):e0190147. https:\/\/doi.org\/10.1371\/journal.pone.0190147.","journal-title":"PLoS ONE"},{"key":"2192_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S104891","volume":"10","author":"I Jacobs","year":"2016","unstructured":"Jacobs I, Singh E, Sewell KL, et al. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016;10:937\u201348. https:\/\/doi.org\/10.2147\/PPA.S104891.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"2192_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1177\/10781552211016099","volume":"27","author":"JCS Soares","year":"2021","unstructured":"Soares JCS, Cavalcanti IDL, Vasconcelos JLA. Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology. J Oncol Pharm Pract. 2021;27(6):1491\u2013502. https:\/\/doi.org\/10.1177\/10781552211016099.","journal-title":"J Oncol Pharm Pract"},{"key":"2192_CR4","unstructured":"English E. Lifesaving cancer treatments denied to public patients due to lengthy delays for HSE approval. Irish Examiner. 2024. Available from: https:\/\/www.irishexaminer.com\/news\/arid-41521586.html. Accessed 27.06.2026."},{"issue":"5","key":"2192_CR5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/10781552211016083","volume":"27","author":"A Safdar","year":"2020","unstructured":"Safdar A, Butt MH, Ahmad A, et al. Progress in oncology biosimilars till 2020: scrutinizing comparative studies of biosimilar monoclonal antibodies. J Oncol Pharm Pract. 2020;27(5):1195\u2013204. https:\/\/doi.org\/10.1177\/10781552211016083.","journal-title":"J Oncol Pharm Pract"},{"key":"2192_CR6","unstructured":"European Medicines Agency. Biosimilars in the EU: Information guide for healthcare professionals. Amsterdam: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 27.06.2026."},{"issue":"4","key":"2192_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355. https:\/\/doi.org\/10.1002\/cpt.1836.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2192_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biologics5010006","volume":"5","author":"SS Aljahili","year":"2025","unstructured":"Aljahili SS, Alshuwairikh SS, AlKhaldi A, et al. Safety of switching from a reference biologic to its biosimilar: a systematic review and meta-analysis. Biologics. 2025;5(1):6. https:\/\/doi.org\/10.3390\/biologics5010006.","journal-title":"Biologics"},{"key":"2192_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2192_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40259-025-00732-2","volume":"39","author":"I Veszelei","year":"2025","unstructured":"Veszelei I, Godman B, Aaltonen K, Selke GW, Garuolien\u0117 K, Cangini A, et al. Introduction of biopharmaceuticals in Europe: a cross-sectional study of early diffusion patterns and data availability. BioDrugs. 2025;39(5):735\u201351.","journal-title":"BioDrugs"},{"issue":"6","key":"2192_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/14712598.2025.2507173","volume":"25","author":"R Schaffel","year":"2025","unstructured":"Schaffel R, Cornes P, Espinoza MA, et al. The potential role of biosimilars in healthcare sustainability in Latin America. Expert Opin Biol Ther. 2025;25(6):633\u201347. https:\/\/doi.org\/10.1080\/14712598.2025.2507173.","journal-title":"Expert Opin Biol Ther"},{"key":"2192_CR12","unstructured":"European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development. Amsterdam: European Medicines Agency; 2025. Available from: https:\/\/www.ema.europa.eu\/. Accessed 27.06.2026."},{"issue":"1","key":"2192_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41523-025-00768-1","volume":"11","author":"S O'Reilly","year":"2025","unstructured":"O\u2019Reilly S, Luis IV, Adam V, et al. Advancing equitable access to innovation in breast cancer. NPJ Breast Cancer. 2025;11(1):71. https:\/\/doi.org\/10.1038\/s41523-025-00768-1.","journal-title":"NPJ Breast Cancer"},{"key":"2192_CR14","unstructured":"European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. Amsterdam: European Medicines Agency; 2022. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-and-heads-medicines-agencies-statement-scientific-rationale-supporting-interchangeability. Accessed 27.06.2026."},{"key":"2192_CR15","doi-asserted-by":"publisher","unstructured":"Rodriguez G, Mancuso J, Lyman GH, et al. ASCO policy statement on biosimilar and interchangeable products in oncology. JCO Oncol Pract. 2023;19(7):411\u2013419. https:\/\/doi.org\/10.1200\/OP.22.0078316.","DOI":"10.1200\/OP.22.00783"},{"key":"2192_CR16","doi-asserted-by":"publisher","unstructured":"Vulto AG, Vanderpuye-Orgle J, van der Graaff M, et al. Sustainability of biosimilars in Europe: a Delphi panel consensus with systematic literature review. Pharmaceuticals (Basel). 2020;13(11):322. https:\/\/doi.org\/10.3390\/ph13110400.","DOI":"10.3390\/ph13110400"},{"key":"2192_CR17","unstructured":"Health Service Executive. Guidance for biological and biosimilar medicines in acute hospitals. Version 2. Dublin: Health Service Executive; 2024. Available from: https:\/\/www.hse.ie\/eng\/about\/who\/acute-hospitals-division\/drugs-management-programme\/protocols\/guidance-for-biological-medicines-in-acute-hospitals.pdf. Accessed 27.06.2026."},{"issue":"1","key":"2192_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11845-023-03480-4","volume":"193","author":"L McCullagh","year":"2024","unstructured":"McCullagh L, Barry M, McCullagh B, et al. Economic impact of biosimilar adoption in oncology in Ireland: opportunities and challenges. Ir J Med Sci. 2024;193(1):161\u201372. https:\/\/doi.org\/10.1007\/s11845-023-03480-4.","journal-title":"Ir J Med Sci"},{"key":"2192_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2016.1272308","volume":"5","author":"C R\u00e9muzat","year":"2017","unstructured":"R\u00e9muzat C, Dorey J, Cristeau O, et al. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5:1272308. https:\/\/doi.org\/10.1080\/20016689.2016.1272308.","journal-title":"J Mark Access Health Policy"},{"issue":"4","key":"2192_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/14737167.2024.2310684","volume":"24","author":"J Mestre-Ferrandiz","year":"2024","unstructured":"Mestre-Ferrandiz J, Czech M, Smolen JS, et al. Leveraging the holistic benefits of biosimilars in Europe\u2014part 2: how payers can safeguard the future of a healthy biosimilar market environment. Expert Rev Pharmacoecon Outcomes Res. 2024;24(4):509\u201319. https:\/\/doi.org\/10.1080\/14737167.2024.2310684.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"2192_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/14737167.2024.2334343","volume":"24","author":"S Simoens","year":"2024","unstructured":"Simoens S, Lacosta TB, Inotai A. Learnings from cross-border biosimilar pricing policies in Europe. Expert Rev Pharmacoecon Outcomes Res. 2024;24(5):585\u20138. https:\/\/doi.org\/10.1080\/14737167.2024.2334343.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2192_CR22","unstructured":"Troein P, Newton M, Stoddart K, et al. The impact of biosimilar competition in Europe. IQVIA Institute for Human Data Science; 2022. Available from: https:\/\/www.iqvia.com\/. Accessed 27.06.2026."},{"key":"2192_CR23","unstructured":"IQVIA Institute for Human Data Science. Global oncology trends 2024: outlook to 2028. IQVIA Institute for Human Data Science; 2024. Available from: https:\/\/www.iqvia.com\/. Accessed 27.06.2026."},{"key":"2192_CR24","unstructured":"IQVIA Institute for Human Data Science. Global oncology trends 2025: outlook to 2029. Parsippany (NJ): IQVIA Institute for Human Data Science; 2025. Available from: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2025. Accessed 27.06.2026."},{"key":"2192_CR25","unstructured":"World Health Organization. A policy analysis of access and inclusion on immune checkpoint inhibitors (PD-1\/PD-L1): financial impact report. Geneva: World Health Organization; 2025. Available from: https:\/\/www.who.int\/. Accessed 27.06.2026."},{"key":"2192_CR26","unstructured":"Parliamentary Budget Office. Public investment in cancer care in Ireland. Publication No. 15 of 2024. Dublin: Houses of the Oireachtas; 2024. Available from: https:\/\/www.drugsandalcohol.ie\/40683\/1\/Public-investment-in-cancer-care-in-ireland_2024.pdf. Accessed 27.06.2026."},{"key":"2192_CR27","unstructured":"Woods N, Brick A, Wren M-A, et al. Public investment in cancer care in Ireland: a systematic analysis, 2013\u20132022. Dublin: Economic and Social Research Institute; 2024. Available from: https:\/\/www.drugsandalcohol.ie\/40683\/1\/Public-investment-in-cancer-care-in-ireland_2024.pdf. Accessed 27.06.2026."},{"key":"2192_CR28","unstructured":"Health Service Executive. Primary Care Reimbursement Service annual report 2023. Dublin: Health Service Executive; 2024. Available from: https:\/\/www.hse.ie\/eng\/staff\/pcrs\/pcrs-publications\/hse-annual-report-2023.pdf. Accessed 27.06.2026."},{"key":"2192_CR29","unstructured":"Health Service Executive Medicines Management Programme. Best-value biological medicine: Long-acting granulocyte colony-stimulating factors on the High Tech Arrangement. Version 1.0. Dublin: Health Service Executive; 2024. Available from: https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/medicines-management\/best-value-medicines\/long-acting-granulocyte-colony-stimulating-factors\/mmp-evaluation-report-bvb-medicines-long-acting-g-csfs.pdf. Accessed 27.06.2026."},{"key":"2192_CR30","unstructured":"Troein P, Newton M, Patel J, et al. The impact of biosimilar competition in Europe. IQVIA Institute for Human Data Science; 2024. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2024.pdf. Accessed 27.06.2026."},{"key":"2192_CR31","unstructured":"European Commission. Biosimilar medicines. Luxembourg: Publications Office of the European Union; 2024. Available from: https:\/\/health.ec.europa.eu\/medicinal-products\/biosimilar-medicines_en. Accessed 27.06.2026."},{"key":"2192_CR32","volume-title":"Assessing the biosimilar void","author":"IQVIA Institute","year":"2025","unstructured":"IQVIA Institute. Assessing the biosimilar void. Parsippany, NJ: IQVIA Institute for Human Data Science; 2025."},{"key":"2192_CR33","unstructured":"Cornes P. Biosimilar medicines: the intersection of access, affordability and innovation. Eur Pharm Rev. 2025."},{"issue":"1","key":"2192_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamaoncol.2024.5032","volume":"11","author":"P Erfani","year":"2025","unstructured":"Erfani P, Okediji RL, Mulema V, et al. Advancing global pharmacoequity in oncology. JAMA Oncol. 2025;11(1):55\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5032.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2192_CR35","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11096-021-01243-0","volume":"43","author":"B Duggan","year":"2021","unstructured":"Duggan B, Smith A, Barry M. Uptake of biosimilars for TNF-alpha inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Int J Clin Pharm. 2021;43(5):1251\u20136. https:\/\/doi.org\/10.1007\/s11096-021-01243-0.","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"2192_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.4938","volume":"6","author":"SS Tu","year":"2025","unstructured":"Tu SS, Rutschman AS. Mapping intellectual property abuses in the pharmaceutical field. JAMA Health Forum. 2025;6(11):e254938. https:\/\/doi.org\/10.1001\/jamahealthforum.2025.4938.","journal-title":"JAMA Health Forum"},{"key":"2192_CR37","doi-asserted-by":"publisher","first-page":"1353177","DOI":"10.3389\/fphar.2024.1353177","volume":"15","author":"S Machado","year":"2024","unstructured":"Machado S, Vogler S, Lepusch\u00fctz L, et al. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Front Pharmacol. 2024;15:1353177. https:\/\/doi.org\/10.3389\/fphar.2024.1353177.","journal-title":"Front Pharmacol"},{"key":"2192_CR38","unstructured":"Donnelly S. Medicinal Products: D\u00e1il \u00c9ireann debate, Tuesday 22 March 2022. Houses of the Oireachtas. Available from: https:\/\/www.oireachtas.ie\/en\/debates\/question\/2022-03-22\/1072\/. Accessed 27.06.2026."},{"issue":"3","key":"2192_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s11845-023-03587-0","volume":"193","author":"KE Coakley","year":"2024","unstructured":"Coakley KE, Bambury RM, McGuinness E, et al. An evaluation of the utilisation of biosimilar monoclonal antibody drugs in Ireland and barriers to their usage. Ir J Med Sci. 2024;193(3):1191\u20139. https:\/\/doi.org\/10.1007\/s11845-023-03587-0.","journal-title":"Ir J Med Sci"},{"key":"2192_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12325-021-01951-z","volume":"39","author":"E Hillhouse","year":"2022","unstructured":"Hillhouse E, Mathurin K, Bibeau J, et al. The economic impact of originator-to-biosimilar non-medical switching in the real-world setting: a systematic literature review. Adv Ther. 2022;39:455\u201387. https:\/\/doi.org\/10.1007\/s12325-021-01951-z.","journal-title":"Adv Ther"},{"issue":"1","key":"2192_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.2765","volume":"113","author":"S Shubow","year":"2023","unstructured":"Shubow S, Sun Q, Nguyen Phan AL, et al. Prescriber perspectives on biosimilar adoption and potential role of clinical pharmacology: a workshop summary. Clin Pharmacol Ther. 2023;113(1):37\u201349. https:\/\/doi.org\/10.1002\/cpt.2765.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2192_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340. https:\/\/doi.org\/10.1007\/s40259-018-0295-0.","journal-title":"BioDrugs"},{"issue":"3","key":"2192_CR43","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/jlb\/lsy022","volume":"5","author":"R Feldman","year":"2018","unstructured":"Feldman R. May your drug price be evergreen. J Law Biosci. 2018;5(3):590\u2013647. https:\/\/doi.org\/10.1093\/jlb\/lsy022.","journal-title":"J Law Biosci"},{"issue":"23","key":"2192_CR44","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMp2407878","volume":"391","author":"B Chao","year":"2024","unstructured":"Chao B, Whalen R, Kesselheim AS, et al. Clearing dense drug-patent thickets. N Engl J Med. 2024;391(23):2180\u20132. https:\/\/doi.org\/10.1056\/NEJMp2407878.","journal-title":"N Engl J Med"},{"key":"2192_CR45","doi-asserted-by":"publisher","unstructured":"Kieran R, Hennessy M, Coakley K, et al. Optimising oncology drug expenditure in Ireland. Ir J Med Sci. 2024;193(4):1735\u20131747. https:\/\/doi.org\/10.1007\/s11845-024-03672-y","DOI":"10.1007\/s11845-024-03672-y"},{"key":"2192_CR46","unstructured":"Safe Affordable Healthcare. Drug wastage. Available from: https:\/\/www.safeaffordablehealthcare.org\/drug-wastage\/. Accessed 27.06.2026."},{"key":"2192_CR47","unstructured":"Medicines Sustainability Taskforce. Available from: https:\/\/www.gov.ie\/en\/collection\/78a7e-medicines-sustainability-taskforce\/. Accessed 27.06.2026."},{"key":"2192_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q166","volume":"385","author":"KB Born","year":"2024","unstructured":"Born KB, Levinson W, Pramesh CS, et al. Choosing wisely in a time of resource constraints. BMJ. 2024;385:q166. https:\/\/doi.org\/10.1136\/bmj.q166.","journal-title":"BMJ"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02192-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:32Z","timestamp":1789117112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02192-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02192-2","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is a commentary article, using publicly available secondary data, ethical approval is not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}